Blog
RSS FeedPosted by Michael Wonder on 10 Jan 2023
Four types of bias in medical AI are running under the FDA’s radar
9 January 2023 - Although artificial intelligence is entering health care with great promise, clinical artificial intelligence tools are prone ...
Posted by Michael Wonder on 21 Nov 2022
Adjustment for baseline characteristics in randomised clinical trials
17 November 2022 - The purpose of randomisation in clinical trials is to ensure that there are no systematic differences between ...
Posted by Michael Wonder on 31 Aug 2022
Reproducibility of real world evidence studies using clinical practice data to inform regulatory and coverage decisions
31 August 2022 - Studies that generate real world evidence on the effects of medical products through analysis of digital data ...
Posted by Michael Wonder on 23 Jun 2022
Industry sponsorship bias in cost effectiveness analysis: registry based analysis
22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...
Posted by Michael Wonder on 23 Mar 2022
Instrumental variables and heterogeneous treatment effects
22 March 2022 - A randomised clinical trial can be used to estimate the average treatment effect for a population. ...
Posted by Michael Wonder on 15 Mar 2022
Collider bias
14 March 2022 - Bias is a systematic, non-random error in the estimation of a treatment effect or the effect of ...
Posted by Michael Wonder on 20 Dec 2021
Biased Outcome reporting Guidelines for Underwhelming Studies (BOGUS) statement and checklist
10 December 2021 - A light hearted article to end the year. Merry Christmas to all our readers. We will ...
Posted by Michael Wonder on 27 Nov 2021
Can we trust strong recommendations based on low quality evidence?
25 November 2021 - A necessary requirement for development of trustworthy guidelines is to respect the relation between the quality (certainty) ...
Posted by Michael Wonder on 26 Oct 2021
Strengthening the reporting of observational studies in epidemiology using Mendelian randomisation: the STROBE-MR Statement
26 October 2021 - An international expert committee, informed by the methodological framework for guideline development of the Enhancing the Quality ...
Posted by Michael Wonder on 26 Oct 2021
Generating high quality evidence from registry based studies
26 October 2021 - EMA has published guidance to provide key methods and good regulatory practices to pharmaceutical organisations on ...
Posted by Michael Wonder on 04 Aug 2021
Interpreting the results of intention to treat, per protocol and as treated analyses of clinical trials
3 August 2021 - Non-adherence in a randomised clinical trial occurs when study participants do not follow the randomly assigned treatment ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 17 Feb 2021
Immortal time bias in observational studies
16 February 2021 - Observational studies are commonly used to evaluate the association between a risk factor or “exposure” and the ...
Posted by Michael Wonder on 14 Dec 2020
From publication bias to lost in information
11 December 2020 - In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical ...
Posted by Michael Wonder on 03 Aug 2020
Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov
27 July 2020 - The coronavirus disease 2019 (COVID-19) pandemic has led to a massive activation of clinical research. ...